Efficacy and safety of an intravenous amikacin-containing regimen as initial therapy in Mycobacterium avium complex pulmonary disease

作者
Tomoki Teramoto,Akihiro Ito,Yosuke Nakanishi,Toru Hashimoto,Tadashi Ishida
出处
期刊:Journal of Clinical Tuberculosis and Other Mycobacterial Diseases [Elsevier BV]
卷期号:44: 100621-100621
标识
DOI:10.1016/j.jctube.2026.100621
摘要

Introduction: complex pulmonary disease (MAC-PD) has been increasing, particularly in Japan. Although current guidelines recommend adding intravenous amikacin (AMK-IV) for cavitary or severe disease, evidence supporting its use as initial therapy remains limited, especially among elderly patients. Methods: This retrospective study included patients with cavitary MAC-PD who received an AMK-IV-containing regimen as initial therapy at Kurashiki Central Hospital between September 2021 and July 2024. AMK-IV dosing was adjusted based on therapeutic drug monitoring (TDM). The primary outcome was sputum culture conversion. Secondary outcomes included radiologic improvement, adverse events, recurrence, and all-cause mortality. Clinical characteristics and outcomes were compared between patients aged ≥75 and < 75 years. Results: = 10; median age, 75 years; 76.2% female). TDM-guided dose adjustment of AMK-IV was performed in all patients, and outpatient treatment was continued using the adjusted dose. Target peak concentrations were achieved in 57.1% of patients, while target trough concentrations were achieved in all patients. At 6/12 months, sputum culture conversion was achieved in 56.3%/62.5% and radiologic improvement was observed in 83.3%/88.9%. No significant differences in sputum culture conversion or radiologic improvement were found between age groups. Treatment discontinuation occurred in two patients (9.5%), whereas 90.9% of elderly patients completed ≥3 months of AMK-IV. Conclusion: AMK-IV added to a standard regimen for cavitary MAC-PD may be effective and safe. In this TDM-guided protocol, favorable outcomes were observed despite lower peak concentrations than those generally recommended.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
麻衣少年完成签到 ,获得积分10
5秒前
挚友发布了新的文献求助10
6秒前
溯whale完成签到,获得积分10
7秒前
luoshikun完成签到,获得积分10
7秒前
popman完成签到 ,获得积分10
8秒前
fxy完成签到 ,获得积分10
11秒前
橘络完成签到 ,获得积分10
12秒前
解方程组完成签到,获得积分10
13秒前
隆zh完成签到 ,获得积分10
16秒前
ZJJ完成签到,获得积分10
16秒前
存慎完成签到 ,获得积分10
19秒前
Aoiny完成签到,获得积分10
21秒前
BAEK完成签到,获得积分10
22秒前
锅锅完成签到 ,获得积分10
22秒前
文曲星座下首席弟子完成签到 ,获得积分10
22秒前
科研通AI6.3的应助被cfw采纳,获得10
23秒前
zxy完成签到 ,获得积分10
24秒前
叮叮当当发布了新的文献求助10
25秒前
要早早睡呀完成签到,获得积分10
25秒前
等待的依波完成签到,获得积分10
28秒前
爱听歌的芷烟完成签到 ,获得积分10
28秒前
gj2221423完成签到 ,获得积分10
29秒前
陆焉识完成签到 ,获得积分10
30秒前
田様的应助被xiongmao2528采纳,获得10
30秒前
32秒前
Anne完成签到 ,获得积分10
33秒前
35秒前
斯文奇迹完成签到 ,获得积分10
36秒前
36秒前
panxingshan完成签到,获得积分10
36秒前
平淡冬亦完成签到 ,获得积分10
37秒前
613完成签到 ,获得积分10
40秒前
墨林云海完成签到,获得积分10
41秒前
Tonald Yang发布了新的文献求助10
41秒前
王木木完成签到,获得积分10
42秒前
Scofield完成签到 ,获得积分10
42秒前
小赵完成签到 ,获得积分10
42秒前
Tender完成签到,获得积分10
43秒前
cfw发布了新的文献求助10
44秒前
烟花的应助被qiuy采纳,获得10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808824
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012